Ivabradine for Chemotherapy-Related Cardiac Dysfunction in Breast Cancer

Yuko Harada 1, Kyosuke Shimada 2, Yukino Kubota 3, Tatsuji Yoshimoto 4

1. Cardiology, Kawasaki Municipal Ida Hospital, Kawasaki, JPN
2. Breast Surgery, Kawasaki Municipal Ida Hospital, Kawasaki, JPN
3. Palliative Medicine, Kawasaki Municipal Ida Hospital, Kawasaki, JPN

Corresponding author: Yuko Harada, adayuko1219@yahoo.co.jp

Abstract

A 55-year-old woman with stage IV breast cancer was diagnosed with heart failure. Her left ventricular ejection fraction (LVEF) had decreased to 37.2%. Chemotherapy-related cardiac dysfunction (CTRCD) was suspected, and standard treatment for heart failure was initiated. After five months, her LVEF remained below 50% since she could not tolerate beta-blockers. Ivabradine was introduced, which remarkably improved her LVEF to 72.6% in only three months. Her myocardium was not dilated, which may be the reason that ivabradine was effective. Ivabradine has shown to be safe and effective in the treatment of CTRCD, and improved activities of daily living of an advanced-stage cancer patient.

Introduction

Breast cancer is the most common cancer among women in Japan [1]. The five-year survival rate is 92.3%, and the first cause of death among female survivors of breast cancer is cardiovascular disease [1,2]. Advances in chemotherapy have reduced the mortality from breast cancer; however, the increase in survival rates has allowed observing the cardiotoxic effects of chemotherapy, which is called chemotherapy-related cardiac dysfunction (CTRCD) [3].

Here we report a case of heart failure with reduced ejection fraction (HFrEF) occurring during chemotherapy for breast cancer. HFrEF is defined as heart failure with a left ventricular ejection fraction (LVEF) less than 40% [4]. Since the patient did not tolerate standard medication for HFrEF, she was prescribed ivabradine, which greatly improved her cardiac function.

Case Presentation

A 55-year-old woman was diagnosed with breast cancer (stage IIIA, T3N1M0) six years ago. Prior to surgery, she was treated with tamoxifen, 5-fluorouracil (500mg/m²), epirubicin (100mg/m²), cyclophosphamide (500mg/m²), and paclitaxel. After surgery, she was treated with tamoxifen for two years and subsequently treated with letrozole for another two years; however, the cancer relapsed. She was initiated on new chemotherapy; however, she had to change anti-cancer drugs due to the adverse side effects of fulvestrant, palbociclib, abemaciclib, paclitaxel, bevacizumab, and medroxyprogesterone acetate, consecutively. Even with chemotherapy, the cancer progressed and metastasized to the bones and liver. She developed dyspnea and systemic edema, and her body weight increased by 10kg in three months.

On admission, her blood pressure was 134/94mmHg, heart rate was 112 beats/minute, and oxygen saturation was 92% (room air). She presented with remarkable edema in both legs. Chest X-ray revealed remarkable pulmonary congestion (Figure 1). Creatinine phosphokinase was only 132 IU/L, but brain natriuretic peptide (BNP) was elevated to 1,747.4 pg/mL. Electrocardiogram revealed sinus tachycardia without ST level change. Echocardiogram revealed diffuse hypo-kinetic heart with reduced LVEF of 37.2%, mild mitral valve regurgitation, and global systolic longitudinal myocardial strain (GLS) of 5.4%.
The patient was diagnosed with HFrEF and was treated with diuretics, mineralocorticoid receptor antagonist (MRA), and beta-blocker. Diuretics was used to treat systemic edema and pleural effusion; however, her systolic blood pressure dropped to 90 mmHg. Therefore, it was difficult to add angiotensin-converting enzyme inhibitor (ACEI) to the minimal dose of beta-blocker. MRA was continued to treat edema and pleural effusion. Her symptoms of dyspnea and edema were resolved, and she was discharged from the hospital in three weeks. However, her LVEF remained below 40%. Beta-blocker carvedilol was initiated to improve cardiac function, but it proved difficult to increase dosage due to her low blood pressure of 85–100mmHg. We tried to discontinue MRA, but her edema relapsed. At five months, her LVEF remained at approximately 40%, and she was not able to walk for more than 10 minutes. Thus, rather than increasing beta-blockers, ivabradine was initiated instead. As a result, her LVEF was normalized to 72.6%, BNP decreased to 34.6 pg/mL, and her exercise endurance was improved in only three months (Figure 2).

The echocardiogram also revealed remarkable improvement in LVEF and GLS (Table 1).
| Time (months) | LVEDd (mm) | LVEsd (mm) | LVEF (%) | GLS (%) | MR |
|--------------|------------|------------|----------|---------|----|
| 0            | 42         | 36         | 37.2     | 5.4     | ++ |
| 1            | 41         | 31         | 38       | 7.4     | ++ |
| 2            | 32         | 25         | 46.1     | 9.2     | +  |
| 4            | 31         | 25         | 47       | 8.2     | +  |
| 6            | 35         | 22         | 63.2     | 16.2    | +  |
| 8            | 39         | 25         | 72.6     | 16.4    | +  |

**TABLE 1: Parameters of echocardiogram during treatment.**

LVEF, GLS, and MR improved after initiating ivabradine at five months. Note that the patient had a small heart.

LVEDd, left ventricular end-diastolic diameter; LVEsd, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; GLS, global systolic longitudinal myocardial strain; MR, mitral regurgitation

**Discussion**

The patient did not have any risk factors for ischemic heart disease nor a family history of cardiac disease. Her sequential echocardiogram findings were normal until three months prior to admission. Therefore, primary cardiomyopathy and ischemic heart disease were excluded from the differential diagnosis. The patient was subsequently diagnosed with HFrEF due to secondary cardiomyopathy. Drug-induced cardiomyopathy was most plausible; however, well-known cardiotoxic agents such as anthracycline or cyclophosphamide were used years ago, and each dose was small. Anthracycline-induced cardiomyopathy is known to be dose dependent and increases with cumulative dose over 400mg/m² [3]. However, the patient used anthracycline only 100mg/m² in total. The other anti-cancer drugs may have caused cardiomyopathy together or may have interacted with each other, but the doses of each drug were small.

CTRCD is difficult to prevent and predict. Even though the patient was carefully monitored, and echocardiogram had shown normal findings until recently, the patient developed CTRCD. Prevention and treatment protocols for CTRCD are not yet established. CTRCD is defined as a decrease in the LVEF of >10 percentage points to a value <53% (normal reference value for two-dimensional echocardiography) [5]. Another parameter, GLS, is considered to be the gold standard for detecting early left ventricular (LV) dysfunction in patients treated with cardiotoxic chemotherapy; a relative percentage reduction of GLS of 15% from baseline is considered abnormal and a marker of early LV subclinical dysfunction [3,6].

There is currently no specific treatment for CTRCD. Therefore, it is treated as chronic heart failure due to other causes. Standard medications for HFpEF are beta-blocker and ACEI or angiotensin receptor blocker (ARB) [7]. However, some patients with HFpEF are not able to tolerate these medications due to low blood pressure.

Ivabradine is a new therapeutic agent that selectively inhibits If current in the sinoatrial node, providing heart rate reduction [7]. It is recommended in the U.S. guidelines for the treatment of HFpEF to initiate and up-titrate beta-blockers to target doses before consideration of ivabradine initiation [7]. In the updated Japanese guideline, ivabradine is also recommended as an additional drug in treating HFpEF with sinus rhythm and heart rate of 75 beats/minutes or higher [4].

An advantage of ivabradine is its safety. It can be used for chronic kidney disease, chronic liver disease, and/or chronic lung disease. Ivabradine has drawn attention as an optimal medication for HFpEF with hypotension and other organ failures to improve ejection fraction (EF) with minimum side effects. Ivabradine is also a promising medication for CTRCD, which usually presents with HFpEF and/or other organ failures.

There are only a few reports on ivabradine use for CTRCD [8-10]. Nakano et al. reported a case of CTRCD by malignant lymphoma, which showed improvement in HFpEF with treatment including ivabradine, but the follow-up period was 30 days [8]. Sarocchi et al. reported a cohort study of 30 patients with CTRCD receiving ivabradine on top of the maximal tolerated dose of ACEI/ARB and beta-blockers, which revealed an increase in LVEF from 45.1% to 53.2% after a mean follow-up of 6.5 months [9]. None of the previous studies reported any adverse effect of ivabradine. The present case has demonstrated significant recovery of EF from 37.2% to 72.6% and of GLS from 5.4% to 16.4% in only three months and furthermore without any adverse effects. As indicated in previous reports, ivabradine has therefore shown to be effective within just a few months.
It is unclear why ivabradine was effective for CTRCD. In the present case, left ventricular end-diastolic diameter (LVEDd) was only 42 mm on admission, which did not change so much from six years ago when LVEDd was 40 mm. Therefore, the cardiac muscle may not have been entirely damaged. Ivabradine may have successfully restored the optimal heart rate to recondition the cardiac muscle. Further studies are needed to reconfirm the reasons why ivabradine is effective for CTRCD.

Ivabradine is optimal for treating CTRCD. The purpose of treating CTRCD is to improve both prognosis and activities of daily living (ADL). Furthermore, ivabradine takes effect within a very short period of time. It is suitable especially for patients with hypotension and/or other organ failures, as it has fewer side effects than other medications.

The follow-up period of our study was less than one year, but the patient was able to enjoy a normal life, which is important for advanced-stage cancer patients.

Conclusions
Ivabradine successfully treated CTRCD, which occurred in a middle-aged cancer patient who could not tolerate beta-blockers. Ivabradine was shown optimal for treating CTRCD as well as improving symptoms and ADL. Further clinical studies are anticipated to determine conditions for initiating such medication.

Additional Information

Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
We would like to thank and acknowledge Dr. Paul W. Chin, Jr. for content discussions and language editing.

References
1. National Cancer Center Japan. Latest Statistics of Cancer . (2021). Accessed: October 4, 2021: https://ganjoho.jp/reg_stat/statistics/stat/summary.html.
2. Patnaik II, Byers T, DiGutteppi C, Dabelea D, Denberg TD: Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011, 13:R64. 10.1186/bcr2901
3. Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, Favuzzi AM: Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018, 22:2175-85. 10.26355/eurrev_201804_14772
4. Tsutsui H, Ide T, Ito H, et al.: JCS/HFSA 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure [Online ahead of print]. Circ J. 2021, 10.1255/circ.JC-21-0431
5. Plana JC, Galderisi M, Barac A, et al.: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014, 27:911-39. 10.1016/j.echo.2014.07.012
6. Voigt JJ, Pedrizetti G, Loyovsky P, et al.: Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVU/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015, 16:1-11. 10.1093/ehjci/jeu184
7. Yancy CW, Jessup M, Bozkurt B, et al.: 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017, 23:628-51. 10.1016/j.cardfail.2017.04.014
8. Nakano Y, Ando H, Suzuki W, Ohashi H, Suzuki Y, Takashima H, Amano T: Impact of ivabradine in uncompensated heart failure due to cancer therapy-related cardiac dysfunction. Clin Case Rep. 2021, 9:e04133. 10.1002/ccr3.4133
9. Sarocchi M, Arboscello E, Ghiglioni G, et al.: Ivabradine in cancer treatment-related left ventricular dysfunction. Chemotherapy. 2018, 63:315-20. 10.1159/000495576
10. de Gregorio C, Potenza G, Ferraro G: Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity. Int J Cardiol. 2014, 176:1574-6. 10.1016/j.ijcard.2014.07.272